Leiomyosarcomas can develop in the uterus, blood vessels, gastrointestinal tract and soft tissues. When the disease becomes unresectable or metastatic, treatment options are limited, and doxorubicin remains one of the established chemotherapy drugs used in advanced disease. Although it can damage cancer cells by interfering with DNA replication and repair, its activity is often constrained by drug resistance, tumor heterogeneity and the ability of malignant tissue to suppress immune attack. The combination explored in this study is intended to confront the tumor on both fronts: direct chemotherapy and immune-system activation.

Ontorpacept is a recombinant fusion protein engineered to block signaling through signal regulatory protein alpha, or SIRPα. The molecule contains a modified form of SIRPα linked to a human antibody fragment. This design allows it to bind CD47, a surface protein frequently displayed at high levels by cancer cells, while preventing CD47 from engaging SIRPα on immune cells. The CD47–SIRPα pathway is commonly described as a “don’t eat me” signal because it can stop macrophages, a type of immune cell, from engulfing abnormal cells.

Under normal conditions, CD47–SIRPα signaling helps protect healthy cells from accidental destruction. Cancer can exploit the same system by increasing CD47 expression or using the pathway to avoid immune surveillance. When ontorpacept interrupts the interaction, macrophages may become more capable of recognizing tumor cells as targets for phagocytosis, the process by which they surround, ingest and digest cellular material. This mechanism does not depend solely on the cancer cell’s ability to divide rapidly, giving the approach a potentially different profile from conventional cytotoxic chemotherapy.

The scientific rationale for combining ontorpacept with doxorubicin is based on the possibility that chemotherapy can make tumors more visible to the immune system. Doxorubicin damages DNA through several complementary mechanisms, including inhibition of topoisomerase II and generation of molecular stress that can injure or kill malignant cells. As tumor cells die, they may release antigens and danger signals that alert immune cells. Blocking CD47–SIRPα signaling at the same time could help macrophages respond to that altered tumor environment and remove cancer cells that would otherwise remain protected.

The trial’s Phase 1/2 structure reflects the two-stage priorities of early cancer-drug development. Phase 1 generally examines safety, tolerability, dose selection and the identification of treatment-related toxicities, while Phase 2 explores preliminary signals of antitumor activity in a defined patient population. In a combination study, investigators must also determine whether the new agent changes the safety profile of chemotherapy or introduces immune-related complications. Particular attention is typically given to blood counts, infusion reactions, infections, organ function and other adverse events relevant to both agents.

This distinction is important because a biologically compelling mechanism does not automatically translate into clinical benefit. Tumors can resist macrophage-mediated clearance through other immune checkpoints, physical barriers in the tumor microenvironment or changes in antigen presentation. Leiomyosarcoma is also genetically and biologically diverse, meaning that CD47 expression, macrophage activity and sensitivity to doxorubicin may vary considerably from one patient to another. The Phase 1/2 investigation is therefore intended not only to test the combination, but also to clarify how it behaves in the complex environment of advanced human cancer.

The study adds to a broader effort to develop therapies that engage the innate immune system. Much recent immuno-oncology research has focused on T cells and checkpoint proteins such as PD-1 and PD-L1. Macrophages, however, are abundant in many solid tumors and can either attack cancer or support its growth, depending on the signals they receive. By targeting CD47–SIRPα communication, ontorpacept is designed to shift macrophage behavior toward tumor-cell removal. The approach may be especially relevant in cancers where immune suppression and dense stromal tissue limit the reach of T-cell-based therapies.

For patients with unresectable or metastatic high-grade leiomyosarcoma, new treatment strategies are urgently needed because advanced disease can progress despite surgery, chemotherapy and other systemic treatments. The combination examined in this trial represents a coordinated attempt to intensify therapy without relying on chemotherapy alone. Its ultimate value will depend on the balance between tumor control, treatment tolerability and the durability of any responses. Results from carefully monitored clinical follow-up will be essential for determining whether disrupting the CD47–SIRPα “don’t eat me” signal can become a meaningful addition to the therapeutic options for this rare and difficult cancer.

Subject of Research: Ontorpacept (TTI-621) combined with doxorubicin for patients with unresectable or metastatic high-grade leiomyosarcoma.

Article Title: A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma.

Article References: Movva, S., Allgood, V., Chugh, R. et al. “A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03574-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41416-026-03574-z

Keywords: ontorpacept, TTI-621, SIRPα, CD47, doxorubicin, leiomyosarcoma, sarcoma, cancer immunotherapy, macrophages, Phase 1/2 clinical trial

Pancreatic cancer is notorious for its late presentation and rapid progression, with most patients receiving a diagnosis only after the disease has metastasized, rendering surgical intervention infeasible. Historically, chemotherapy has been the cornerstone of treatment for these patients, yet survival rates remain dismal, with less than one year median overall survival and limited benefits from subsequent lines of therapy. The urgent need for novel, targeted therapeutics has driven extensive research into the molecular underpinnings of this aggressive tumor type.

KRAS mutations lie at the heart of pancreatic cancer pathogenesis, present in over 90% of cases, driving oncogenic signaling that fuels tumor growth and metastasis. For decades, KRAS was deemed “undruggable” due to its high affinity for GTP/GDP and lack of suitable binding pockets, thwarting traditional small molecule inhibition strategies. However, a paradigm shift occurred roughly ten years ago with the advent of covalent inhibitors targeting specific KRAS mutants, particularly KRAS G12C, which are more prevalent in lung and colorectal cancers but rare in pancreatic tumors.

Daraxonrasib distinguishes itself as a RAS(ON) multi-selective inhibitor that uniquely targets the spectrum of KRAS mutations commonly found in pancreatic cancer, including but not limited to G12D and G12V mutations. Mechanistically, daraxonrasib operates as a molecular glue that facilitates the stable association of mutant RAS proteins with cyclophilin A, a peptidyl-prolyl isomerase, thereby obstructing downstream RAS signaling pathways critical for tumor cell survival and proliferation. Administered orally as a daily pill, daraxonrasib offers a convenient route of administration for patients often burdened by intensive chemotherapy regimens.

Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research and lead investigator, emphasized the transformative potential of this agent, stating that daraxonrasib could become a broadly applicable targeted therapy for nearly all patients with advanced pancreatic cancer if ongoing and future clinical trials corroborate these initial results. The phase 1/2 trial enrolled 168 heavily pretreated patients, all harboring RAS mutations, most of whom had undergone one or more lines of chemotherapy prior to study enrollment.

Safety analysis revealed that while many patients experienced side effects—most commonly rash, mucositis, nausea, and diarrhea—these adverse events were generally manageable with supportive care. The tolerability profile of daraxonrasib proved favorable, facilitating sustained treatment adherence, which is paramount in this fragile patient population. This safety and tolerability profile supports further development and intensification of phase 3 trials.

Efficacy endpoints offer a promising glimpse into daraxonrasib’s therapeutic activity. At the recommended phase 2 dose of 300 mg once daily, approximately 30% of patients with one prior line of therapy achieved an objective tumor response, a remarkable figure given the refractory nature of their disease. Even more encouragingly, roughly 90% of patients experienced disease control, defined as tumor shrinkage or stabilization, across all prior treatment strata. The median duration of response extended beyond eight months for patients with limited prior therapy, illustrating meaningful clinical benefit.

The RASolute 302 study, an ongoing randomized phase 3 trial, will rigorously assess whether daraxonrasib can supplant current second-line chemotherapy as the therapeutic standard. Designed to directly compare efficacy, progression-free survival, and overall survival, this trial represents a critical next step in validating RAS inhibition as a cornerstone of pancreatic cancer treatment. Dr. Wolpin’s upcoming plenary presentation at the 2026 American Society for Clinical Oncology Annual Meeting is highly anticipated by the oncology community.

Crucially, daraxonrasib heralds not only a novel therapeutic agent but symbolizes a paradigm shift in targeting the RAS oncogene, historically one of the most challenging molecular targets in oncology. Its multi-selective activity across prevalent pancreatic cancer RAS mutations and its unique mechanism disrupting RAS-cyclophilin A interaction distinguish it from earlier mutation-specific inhibitors that have limited scope in this tumor type.

The pursuit of mutant RAS inhibition embodies years of concerted efforts from chemists, molecular biologists, oncologists, and patient advocates, culminating in this innovative approach that transforms a previously “undruggable” target into a viable therapeutic vulnerability. This evolving class of RAS inhibitors, including several other candidates now entering clinical trials, may soon redefine treatment algorithms for pancreatic and other RAS-driven cancers.

While considerable challenges remain—including optimizing combination therapies, overcoming resistance mechanisms, and managing long-term toxicities—daraxonrasib’s success signals a new dawn in pancreatic cancer therapy. It offers renewed hope that targeted inhibition of a fundamental oncogenic driver can translate to durable responses and improved survival outcomes for patients afflicted with this devastating disease.

Funding for this research was provided by Revolution Medicines, underscoring the critical collaboration between academic investigators and industry partners in advancing translational oncology. The Dana-Farber Cancer Institute continues to lead innovation in cancer research and treatment, aiming to transform scientific breakthroughs into life-extending therapies for patients worldwide.

Subject of Research: Targeted inhibition of RAS mutations in advanced pancreatic cancer
Article Title: Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
News Publication Date: 7-May-2026
Web References: https://www.nejm.org/doi/full/10.1056/NEJMoa2505783
References: New England Journal of Medicine, DOI: 10.1056/NEJMoa2505783
Image Credits: Dana-Farber Cancer Institute
Keywords: Pancreatic cancer, RAS mutation, KRAS, daraxonrasib, targeted therapy, molecular glue, clinical trial, phase 1/2, phase 3, RASolute 302, oncology, new drug development

Integral to this research is the harnessing of CD133+ hematopoietic stem cells, distinguished by their potent multipotency and capacity to differentiate into various mesenchymal lineage cells. By isolating these progenitor cells from the patients’ own bone marrow, researchers significantly mitigate immune rejection risks, optimizing cell survival and integration post-transplantation. This autologous strategy ensures that therapeutic cells are biologically compatible, obviating the need for long-term immunosuppression and addressing a critical limitation in earlier cell-based treatments. The selection of CD133+ cells is particularly strategic; these markers identify a subpopulation known for robust angiogenic potential and tissue regenerative influence, attributes essential for reconstructing the damaged endometrial lining inherent in Asherman Syndrome.

The methodology of the phase 1/2 trial meticulously assessed the safety, feasibility, and preliminary efficacy of delivering autologous CD133+ cells to patients diagnosed with moderate to severe intrauterine adhesions. Following bone marrow aspiration under controlled conditions, the stem cells were purified, expanded ex vivo, and subsequently transplanted directly into the uterine cavity via hysteroscopic guidance. This precise delivery technique ensures that the regenerative cells localize within the pathological niche, maximizing therapeutic impact while minimizing systemic distribution. Throughout the study, patients underwent serial evaluations encompassing imaging modalities, endometrial biopsies, and clinical assessments to monitor tissue regeneration and symptom amelioration.

Safety data emerging from the trial was exceptionally encouraging, showcasing no serious adverse events attributable to the cell therapy. Patients tolerated the intervention well, with only minor procedural discomforts reported, underscoring the feasibility of this approach in a clinical setting. Furthermore, the trial demonstrated promising signs of endometrial regeneration, evidenced by increases in endometrial thickness and enhanced vascularization observed via Doppler ultrasound. Histological analyses substantiated these findings, revealing re-epithelialization and restoration of stromal architecture—the cardinal indicators of functional endometrial repair. Such regenerative outcomes highlight the potential transformative effect of CD133+ stem cell therapy on uterine biology.

Beyond morphological regeneration, the trial evaluated fertility-related endpoints, marking a critical dimension for patients striving to conceive. Preliminary results indicated successful pregnancies in a subset of treated individuals, an outcome unattainable with conventional surgical adhesiolysis alone. This breakthrough suggests that stem cell-induced endometrial restoration may not only repair structural defects but also reestablish the physiological environment conducive to embryo implantation and pregnancy maintenance. These findings affirm the hypothesis that tissue-specific progenitor cells can recapitulate the complex stromal, vascular, and epithelial milieu necessary for reproductive success.

Mechanistically, the regenerative efficacy of CD133+ bone marrow-derived stem cells likely stems from their paracrine signaling activities, immunomodulatory functions, and differentiation capacities. Secreted factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) promote angiogenesis, crucial for revascularization of scarred endometrial tissue. Simultaneously, these cells attenuate local inflammatory cascades that exacerbate fibrosis, thereby favoring an environment permissive to healing. The ability of these progenitor cells to differentiate into endometrial stromal and epithelial lineages further substantiates their direct role in tissue reconstruction. This multifaceted interplay of cellular and molecular mechanisms underpins the observed clinical improvements.

Another critical aspect examined in this investigation is the long-term sustainability of the regenerative response. Follow-ups at six and twelve months post-transplantation revealed persistence of functional endometrial improvements, suggesting durable engraftment or persistent paracrine stimulation by the transplanted cells. This durability is essential for ensuring sustained fertility restoration and underscores the potential of autologous stem cell therapy as a durable remedy rather than a transient palliative measure. Longer-term studies will be required to assess durability beyond the first year, but current data are highly promising.

The trial’s design also accounted for rigorous quality control in stem cell isolation and expansion processes, addressing one of the primary challenges in translating cell therapy to widespread clinical use. Standardization of collection protocols, cell sorting via flow cytometry for CD133+ markers, and cultured expansion under Good Manufacturing Practice (GMP) conditions ensured reproducibility and scalability. Such stringent procedural adherence enhances the credibility of the findings and lays a foundational framework for future multicenter trials aiming to confirm efficacy and safety across varied populations and healthcare settings.

Importantly, this pioneering therapy not only augments the armamentarium against Asherman Syndrome but also opens investigative pathways for other gynecological and reproductive disorders characterized by tissue scarring and regeneration deficits. Endometrial thinning, recurrent implantation failure, and even premature ovarian insufficiency might, in the future, be amenable to similar autologous stem cell-based reparative strategies. The insights garnered here catalyze a burgeoning field of regenerative reproductive medicine, blending cellular biology, clinical innovation, and patient-centric care in novel and transformative ways.

The social and psychological ramifications of such advancements are profound. Asherman Syndrome often leads to devastating infertility and emotional distress. By offering tangible, regenerative solutions that restore uterine function and fertility potential, this therapy transcends conventional treatment limitations and enhances quality of life for countless women. Furthermore, the autologous nature of the approach aligns with personalized medicine trends, fostering patient trust and therapeutic adherence by minimizing foreign material exposure and optimizing biological compatibility.

From a regulatory standpoint, the successful completion of this phase 1/2 trial provides pivotal impetus for advancing toward larger, randomized controlled phase 3 studies. Regulatory agencies, ever cautious with cell-based interventions, will scrutinize extended safety and efficacy data. Nonetheless, the meticulous and transparent reporting of this trial’s outcomes fosters confidence in the therapy’s viability and aligns with global efforts to integrate regenerative medicine into standard clinical repertoires responsibly.

Future research directions are manifold. Refinement of the cell delivery mechanisms, such as employing scaffold-based systems to enhance cell retention and survival within the endometrium, represents a fascinating frontier. Moreover, elucidating the molecular signals governing the homing and integration of CD133+ cells will deepen mechanistic understanding and potentially enhance therapeutic efficiency. Combined approaches incorporating hormonal modulation or adjunctive pharmacotherapies might synergistically amplify regenerative outcomes. The intersection of bioengineering, molecular biology, and clinical science is poised to accelerate the translation of these innovations.

In conclusion, the deployment of autologous CD133+ bone marrow-derived stem cells in treating Asherman Syndrome epitomizes the convergence of cutting-edge stem cell biology with clinical exigency. This phase 1/2 trial not only showcases the feasibility and safety of such cell therapies but also charts a course for efficacious regeneration of a notoriously challenging condition affecting female reproductive health. As we stand on the cusp of a new era in regenerative gynecology, the implications for fertility restoration, hormonal homeostasis, and holistic wellbeing are both exciting and profound. Continued exploration and rigorous validation will solidify this transformative approach’s place in medical history.

Subject of Research: Autologous cell therapy using CD133+ bone marrow-derived stem cells for the treatment of Asherman Syndrome and its effects on uterine tissue regeneration and fertility restoration.

Article Title: Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial.

Article References:
Santamaria, X., Pardo-Figuerez, M., González-Fernández, J. et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial. Nat Commun (2026). https://doi.org/10.1038/s41467-025-67850-x

Image Credits: AI Generated